曲妥珠单抗联合CTF化疗方案对乳腺癌晚期患者心肌酶谱及毒副反应的影响被引量：1

Effects of trastuzumab combined with CTF chemotherapy regimen on myocardial zymogram and toxic side effects in patients with advanced breast cancer

在线阅读下载PDF

导出

摘要目的探讨曲妥珠单抗联合CTF[环磷酰胺+吡柔比星+5-氟尿嘧啶]化疗方案对乳腺癌晚期患者心肌酶谱及毒副反应的影响。方法回顾性分析2018年1月至2020年2月本院收治的80例乳腺癌晚期患者的临床资料,根据治疗方法不同分为对照组(n=41)与观察组(n=39)。对照组采用CTF治疗,观察组采用曲妥珠单抗联合CTF治疗,比较两组心肌酶谱指标[心肌肌钙蛋白I(cTnI)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)]及毒副反应。结果治疗5个周期,两组cTnI、CK、CK-MB水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组白细胞降低、恶心呕吐、脱发及心功能比较差异无统计学意义。结论曲妥珠单抗联合CTF化疗治疗可降低乳腺癌晚期患者心肌酶谱水平,且安全性较高。

作者赵伶伶 ZHAO Lingling

机构地区铁岭市中心医院肿瘤内科

出处《当代医学》 2022年第6期104-106,共3页 Contemporary Medicine

关键词乳腺癌 CTF化疗曲妥珠单抗心肌酶谱毒副反应

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1刘伟,李健斌,王涛,边莉,张少华,张会强,周金妹,宋三泰,江泽飞.蒽环类联合紫杉类方案在乳腺癌新辅助化疗中的有效性及安全性评价[J].临床肿瘤学杂志,2016,21(3):228-232. 被引量：27
2黄玥,朱华.乳腺导管内癌伴微浸润患者术后行CEF与CTF方案化疗的效果比较[J].山东医药,2017,57(10):65-66. 被引量：5
3胡赛男,张莉莉.跨线曲妥珠单抗联合不同化疗方案治疗HER2阳性晚期乳腺癌的临床研究[J].肿瘤防治研究,2016,43(1):39-44. 被引量：28
4中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692-754. 被引量：1225
5皋文君,刘砚燕,袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J].肿瘤,2012,32(2):142-144. 被引量：544
6黄仁峰,雷睿文,欧林洋.局部晚期乳腺癌的新辅助化疗联合手术治疗的疗效观察[J].当代医学,2017,23(33):109-110. 被引量：9
7李剑,赵二保,畅俊平.表柔比星及环磷酰胺序贯多西他赛联合曲妥珠单抗对乳腺癌患者心功能影响的研究[J].中国药物与临床,2018,18(4):581-582. 被引量：16
8胡月珍.曲妥珠单抗与蒽环类药物不同联合治疗方案对乳腺癌的疗效及患者心脏功能的影响[J].实用癌症杂志,2016,31(10):1684-1686. 被引量：14
9王灿,丁昊.曲妥珠单抗、卡铂及多西他赛联合治疗乳腺癌的疗效及安全性评价[J].实用癌症杂志,2017,32(11):1896-1898. 被引量：12

二级参考文献82

1卜擎燕,熊宁宁,邹建东,蒋萌,刘芳,Anna Zhao-Wong.ICH国际医学用语词典(MedDRA):药事管理的标准医学术语集[J].中国临床药理学与治疗学,2007,12(5):586-590. 被引量：41
2Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine[J]. Oneologist, 2009, 14(4): 320-68.
3Sinn P, Aulmann S, Wirtz R, et al. Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility[J]. Geburtshilfe Frauenheilkd, 2013, 73 (9): 932-40.
4Ahmed S, Sami A, Xiang J. HER2-directed therapy: current treatment options for HER2-positive breast cancer[J]. Breast Cancer, 2015, 22(2): 101-16.
5Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J]. N Engl J Med, 2001, 344(11): 783-92.
6Marry M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group[J]. J Clin Oncol, 2005, 23(19): 4265-74.
7Gasparini G, Gion M, Mariani L, et al. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer[J]. Breast Cancer Res Treat, 2007, 101(3): 355-65.
8Burstein H J, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study[J]. Cancer, 2007, Sep 1; 110(5): 965-72.
9Yamamoto D, Iwase S, Kitamura K, et al. A phase 1I study of trastuzumab and capecitabine for patients with HER2- overexpressing metastatic breast cancer: Japan Breast Cancer.Research Network (JBCRN) O0 Trial[J]. Cancer Chemother Pharmacol, 2008, 61(3): 509-14.
10Yardley DA, Burris HA 3rd, Simons L, et al. A phase lI trial of gemcitabine/carboplatin with or without trastuzumab in the first- line treatment of patients with metastatic breast cancer[J]. Clin Breast Cancer, 2008, 8(5): 425-31.